Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Leuk Lymphoma. 2021 Aug;62(8):1892-1896. doi: 10.1080/10428194.2021.1885665. Epub 2021 Feb 18.
To achieve prompt and comprehensive assessment of treatment, we investigated the feasibility of composite hematologic and organ response (CHOR) model in a Chinese light chain (AL) amyloidosis cohort. Three hundred and eighty-eight newly diagnosed patients were assigned scores of 0-3 for complete response, very good partial response, partial response, no response, or progression at 6 months. Organ response (OR) was scored as follows: 0 - all OR (AOR), 1 - mixed OR (MOR), and 2 - no OR (NOR). Finally, patients were divided into CHOR group 1 (total score 0-3) and group 2 (total score 4-5). The patients who achieved AOR and MOR had similar outcomes, which were much better than those of patients with NOR. Group 1 had significantly better overall survival than group 2 (< .001). The CHOR model had a significantly higher predictive power of survival than hematologic response and OR. We validated the value of the CHOR model as an early indicator of treatment benefit.
为了实现对治疗的快速和全面评估，我们在中国轻链（AL）淀粉样变性患者队列中研究了复合血液学和器官反应（CHOR）模型的可行性。388 例新诊断的患者在 6 个月时被分配为完全缓解、非常好的部分缓解、部分缓解、无反应或进展的 0-3 分。器官反应（OR）的评分如下：0-所有 OR（AOR）、1-混合 OR（MOR）和 2-无 OR（NOR）。最后，患者被分为 CHOR 组 1（总分 0-3）和组 2（总分 4-5）。达到 AOR 和 MOR 的患者具有相似的结局，明显优于 NOR 患者。组 1 的总生存率明显高于组 2（<0.001）。CHOR 模型对生存的预测能力明显高于血液学反应和 OR。我们验证了 CHOR 模型作为治疗获益早期指标的价值。
